Takeda, Frazer Launch Phantom Pharmaceuticals to Spur Development of GI Drug Vonoprazan
The drug remains unapproved in European and the U.S. markets. Takeda has granted Phantom a license and exclusive commercialization rights to the drug in Europe, the U.S. and Canada.